AzTrials
AzTrials

Autism Spectrum DisordersNCT02200679

National Study on Autism Spectrum Disorder in China

An observational study of Autism Spectrum Disorders, run by Fudan University at 8 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aims of the national population-based study on Autism Spectrum Disorder (ASD) include: (1) to understand the overall prevalence of ASD in children aged 6-12 years in 8 cities (n=120,000), (2) to explore environmental and genetic risk factors associated with ASD Read more about this study

Who is it for?
Ages 6 to 12 years
Conditions the study is for
Autism Spectrum Disorders
How many people
143,755 participants
Where
8 sitesChina
Study dates
Jan 2014to Dec 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Community-based populations aged 6-12 years old form 8 cities in China

Who may be able to join

  • All children aged 6-12 years old and have lived in the recruied community over 6 months.

Who cannot join

  • None

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

China8 sites
  • Capital Institute of Pediatrics

    Beijing, Beijing Municipality

  • Central South University

    Changsha, Hunan

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan

  • Sichuan University

    Chengdu, Sichuan

  • Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality

  • The Third Affiliated Hosptial,Sun Yat-Sen University

    Guangzhou, Guangdong

  • Harbin Medical University

    Harbin, Heilongjiang

  • The 2nd Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang

Other trials in China

About this study

Official title: Study on Approach and Standards for Diagnosis, Prevention and Control of Autism Spectrum Disorder in Children in China

The aims of the national population-based study on Autism Spectrum Disorder (ASD) include: (1) to understand the overall prevalence of ASD in children aged 6-12 years in 8 cities (n=120,000), (2) to explore environmental and genetic risk factors associated with ASD

Read the detailed description

The study is a multicenter, cross-sectional study involing eight cities. The program includes a prevalence study and a risk factors analysis.

  1. Prevalence study on ASD To estimate the national prevalence of ASD in Chinese pediatric population aged 6-12 years. 1.1. Target population This 4-year study is initiated in the year of 2013 in eight cities of China . For each city, 3 communities with different economic levels were chosen including all children born within Jan 2001 to Dec 2007 (ages 6-12 years at screening) with local residency or have lived in the community over 6 months. The ASD children who are attending special education schools and meet with the inclusion criteria will also be included in the prevalence estimation. 1.2. Sample size Based on the previous regional studies , we plan to recruit approx.15, 000 subjects for each city (average. 5,000 subjects for each community), and 120,000 subjects in total then comprise the national study sample. The plan will be updated, based on the prevalence obtained in the pilot study. 1.3. Screening and diagnosis The screening tool will be chosen from Autism Spectrum Rating Scale (ASRS) or SRS(Social Responsiveness Scale) after pilot study.The questionnaire is a parent-administered form that takes approximately 15-20 minutes to complete. Parents of recruied children were invited to complete the questionnaire. Parents of all questionnaire screen-positive children will be contacted for appointing further diagnostic evaluations. Children whose parents could not be reached are classified as non-responders. The DSM-Ⅳ, ADI-R and ADOS (ADI-R: Autism Diagnosis Interview-Revised, ADOS: Autism Diagnosis Observation Scales) are used for diagnostic evaluations. Co-morbidities, such as epilepsy and ADHD (Attention Deficit Hyperactivity Disorder )after aditional medical examinations such as, EEG(electroencephalogram), head circumference, anthropometrics, allergies, sleep patterns, etc.
  2. Risk Factors study on ASD A classic case-control design is applied to explore the risk factors of ASD. 2.1. Study subjects 2.1.1. Cases and control Cases were children living in target communities who are identified as positive based on questionnaire screen and the subsequent diagnosis with DSM-Ⅳ, ADOS and ADI-R.

Controls were children who are screened to be negative and matched to cases by age, gender, and class.

2.2. Environmental pollutants exposures Given the hypothesis that environmental factors might play a role in the etiology of ASD, we will analyze the biological samples of the subjects to investigate environmental exposures including chronic lead exposure, pesticides exposure, and endocrine disruptors exposure , for which, hair, blood, and urine will be collected for cases and controls. The detailed protocol for the measurement of each kind of biological sample has been introduced everywhere (see the references in individual block).

2.3. Analysis of other potential risk factors This study will also analyze the association between the onset of ASD and other risk factors, including diet (), living environment(),perinatal characteristics of parents, feeding history, baby growth and development after birth by using questionnaire and reviewing medical records.

2.4. Genetic analysis We are going to use the targeted area capture technology developed before and HiSeq2000, the second generation of high throughput sequencing platform, to carry out the molecular diagnosis screening (monogenic disease). Also, we will screen through Trio those ASD-related genetic mutations that are of high credibility and occur frequently so as to classify ASDs according to their definite etiologies.Furthermore, we will continue the study on the distribution of ASD relevant gene mutations among patients in China, which will lay a solid foundation for further studies of molecular epidemiology.Meanwhile, we will also apply genome-wide sequencing technology on the positive cases so as to find new mutation that might serve as potential molecular markers facilitating the diagnosis and treatment of ASDs.

A pilot study involving 4 cities (n=400 for each, in total n>=1600)will be conducted to test all methodology that will be applied in the prevalence study. A diagnostic study will be performed to evalute the performance of ASRS and SRS in screening ASD, one of which will be applied in the main study.

Keywords
Autism spectrum disorders, Prevalence, Diagnosis, Screen, Risk Factor, SRS, ASRS
Medical subject headings
Autism Spectrum Disorder, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02200679
Study groupRoleWhat they receive
Autism Spectrum DisordersCases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. prevalence of autism spectrum disorder

    The outcome of the study include ASD and its commorbidities. The disease occurs in children as early as 18 months old, however the confirmation of diagnosis usually is 3 or later. 6-12 years is time frame for confirmed diagnosis.

    Measured: 3-12 years

Secondary outcomes (3)
  1. ASRS

    ASRS is a measure for screen ASD.

    Measured: 6-18 years

  2. ADI-R

    The ADI-R is a good diagnosis tool for children with ASD

    Measured: 4-18 yeas

  3. ADOS

    The ADOS is a appropriate instrutment for ASD diagnosis.

    Measured: 14months-16 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jul 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionDec 2016
  4. Study completionDec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
143,755 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02200679
Sponsor's protocol ID
201302002
Status last verified
May 2017
First submitted
24 Jul 2014
Last updated
16 May 2017
Results posted
No
Data monitoring committee
Yes

Publications

  • Yan W, Siegert RJ, Zhou H, Zou X, Wu L, Luo X, Li T, Huang Y, Guan H, Chen X, Mao M, Xia K, Zhang L, Li E, Li C, Zhang X, Zhou Y, Shih A, Fombonne E, Zheng Y, Han J, Sun Z, Jiang YH, Wang Y. Psychometric properties of the Chinese Parent Version of the Autism Spectrum Rating Scale: Rasch analysis. Autism. 2021 Oct;25(7):1872-1884. doi: 10.1177/13623613211004054. Epub 2021 Apr 12.

    PubMed 33845648
  • Zhou H, Zhang L, Wu L, Zou X, Luo X, Xia K, Wang Y, Xu X, Ge X, Sun C, Deng H, Fombonne E, Jiang YH, Yan W, Wang Y. Validity and reliability analysis of the Chinese parent version of the Autism Spectrum Rating Scale (6-18 years). Psychiatry Res. 2015 Dec 15;230(2):255-61. doi: 10.1016/j.psychres.2015.09.003. Epub 2015 Sep 8.

    PubMed 26384573

Questions about this trial

What is this clinical trial studying?

An observational study of Autism Spectrum Disorders, run by Fudan University at 8 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

prevalence of autism spectrum disorder (time frame: 3-12 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02200679, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in